ИСПОЛЬЗОВАНИЕ ПРЯМЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРИ ПОДГОТОВКЕ К ЭЛЕКТРИЧЕСКОЙ КАРДИОВЕРСИИ
Аннотация
С целью оценки эффективности и безопасности коротких курсов прямых пероральных антикоагулянтов для подготовки к проведению электрической кардиоверсии у больных с неклапанной фибрилляцией предсердий в сравнении с терапией варфарином обследованы 174 пациента с длительностью аритмии более 48 часов.
Об авторах
Н. А. Новикова
ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова»
Россия
Россия
А. Н. Воловченко
ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова»
Россия
Россия
Список литературы
1. Arias M.A., Casares-Medrano J., Pacho'n M., Puchol A. Silent embolism after electrical cardioversion of atrial fibrillation: what does brain magnetic resonance imaging provide? Rev Esp Cardiol 2012; 65: 489.
2. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: 967-975.
3. Moreyra E., Finkelhor R.S., Cebul R.D. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J. 1995; 129(1): 71-75.
4. Klein A., Grimm R., Murray D., Apperson-Hansen C., Asinger R.W., Black LWet al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-20.
5. Camm A.J., Lip G.Y.H., De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
6. Connolly S.J., Ezekowitz M.D., Yusuf S. et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. NEnglJ Med 2009; 361: 1139-1151.
7. Patel M.R., Mahaffey K.W., Garg J. et al, ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
8. Granger C.B., Alexander J.H., McMurray J.J. et al, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
9. Nagarakanti R., Ezekowitz M.D., Oldgren J. et al. Dabiga-tran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136.
10. Piccini J.P., Stevens S.R., Lokhnygina Y. et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013; 61: 1998-2006.
11. Flaker G., Lopes R.D., Al Khatib S.M. et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014; 63: 1082-1087.
12. Nagarakanti R., Ezekowitz M., Oldgren J. et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-36.
13. Kalejs O., Sakne S., Litunenko O. et al. Safety and efficacy of Dabigatran versus Warfarin in patients with persistent and long-Acting atrial fibrillation undergoing electrical cardioversion. J Am Coll Cardiol. 2014; 63.
14. Kalejs O., Sakne S., Litunenko O. et al. Two dosages Dabigatran versus Warfarin in patients with high risk of stroke and embolism undergoing electrical cardioversion with persistent and long-acting atrial fibrillation. J Am Coll Cardiol. 2015; 65.
15. Johansson A.K., Juhlin T., Engdahl J. et al. Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism? Europace. 2015.
16. Yadlapati A., Groh C., Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol. 2014 Apr 15; 113(8): 1362-3.
17. Caldeira D., Costa J., Ferreira J.J., Lip G.Y., Pinto F.J. Nonvitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol. 2015 Jul; 104(7): 582-90.
18. Law E.H., Gordon W. Target-specific oral anticoagulants in patients undergoing cardioversion. Am J Health Syst Pharm. 2014 Jul 15; 71(14): 1171-6.
19. Coleman C., Khalaf S., Mould S et al. Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. Pacing Clin Electrophysiol. 2015 Jun; 38(6): 731-7.
20. Pallisgaard J.L., Lindhardt T.B., Hansen M.L. et al. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study. PLoS One. 2015 Oct 29; 10(10).
21. Cappato R., Ezekowitz M.D., Klein A.L. et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014.
22. Patel M.R., Mahaffey K.W., Garg J. et al, the ROCKET AF Steering Committee, for the ROCKET AF Investigator. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891.
Рецензия
Для цитирования:
Новикова Н.А., Воловченко А.Н. ИСПОЛЬЗОВАНИЕ ПРЯМЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРИ ПОДГОТОВКЕ К ЭЛЕКТРИЧЕСКОЙ КАРДИОВЕРСИИ. Вестник аритмологии. 2017;(88):18-24.
For citation:
Novikova N.A., Volovchenko A.N. DIRECT ORAL ANTICOAGULANTS DURING PREPARATION TO ELECTRIC CARDIOVERSION. Journal of Arrhythmology. 2017;(88):18-24. (In Russ.)
Просмотров:
162
Послать статью по эл. почте 